1. Home
  2. ANNX vs NREF Comparison

ANNX vs NREF Comparison

Compare ANNX & NREF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANNX
  • NREF
  • Stock Information
  • Founded
  • ANNX 2011
  • NREF 2019
  • Country
  • ANNX United States
  • NREF United States
  • Employees
  • ANNX N/A
  • NREF N/A
  • Industry
  • ANNX Biotechnology: Pharmaceutical Preparations
  • NREF Real Estate Investment Trusts
  • Sector
  • ANNX Health Care
  • NREF Real Estate
  • Exchange
  • ANNX Nasdaq
  • NREF Nasdaq
  • Market Cap
  • ANNX 263.3M
  • NREF 244.3M
  • IPO Year
  • ANNX 2020
  • NREF 2020
  • Fundamental
  • Price
  • ANNX $2.42
  • NREF $13.79
  • Analyst Decision
  • ANNX Strong Buy
  • NREF Hold
  • Analyst Count
  • ANNX 4
  • NREF 4
  • Target Price
  • ANNX $12.50
  • NREF $14.75
  • AVG Volume (30 Days)
  • ANNX 1.7M
  • NREF 43.3K
  • Earning Date
  • ANNX 08-11-2025
  • NREF 07-31-2025
  • Dividend Yield
  • ANNX N/A
  • NREF 14.67%
  • EPS Growth
  • ANNX N/A
  • NREF N/A
  • EPS
  • ANNX N/A
  • NREF 3.00
  • Revenue
  • ANNX N/A
  • NREF $123,447,000.00
  • Revenue This Year
  • ANNX N/A
  • NREF $27.69
  • Revenue Next Year
  • ANNX N/A
  • NREF $5.49
  • P/E Ratio
  • ANNX N/A
  • NREF $4.55
  • Revenue Growth
  • ANNX N/A
  • NREF 337.68
  • 52 Week Low
  • ANNX $1.29
  • NREF $12.14
  • 52 Week High
  • ANNX $7.85
  • NREF $18.09
  • Technical
  • Relative Strength Index (RSI)
  • ANNX 47.32
  • NREF 44.05
  • Support Level
  • ANNX $2.29
  • NREF $13.24
  • Resistance Level
  • ANNX $2.62
  • NREF $14.58
  • Average True Range (ATR)
  • ANNX 0.17
  • NREF 0.34
  • MACD
  • ANNX -0.01
  • NREF -0.05
  • Stochastic Oscillator
  • ANNX 37.74
  • NREF 37.75

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

About NREF NexPoint Real Estate Finance Inc.

NexPoint Real Estate Finance Inc is a real estate investment trust. The company provides structured financing solutions by investing in mid-sized multifamily, storage and select-service, and extended-stay hospitality properties. Its investment objective is to generate attractive, risk-adjusted returns for stockholders over the long term. The Company is focused on originating, structuring and investing in first-lien mortgage loans, mezzanine loans, preferred equity, convertible notes, multifamily properties, and common equity investments, as well as multi-family and single-family rental ("SFR") commercial mortgage-backed securities securitizations ("CMBS securitizations"), multifamily structured credit risk notes ("MSCR Notes") and mortgage-backed securities.

Share on Social Networks: